
HALO
Halozyme Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 0
Sell signal 2
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About HALO
Halozyme Therapeutics, Inc.
A biopharmaceutical company that develops recombinant human enzymes and novel oncology therapies for the tumor microenvironment
Biological Technology
Invalid Date
05/10/2007
NASDAQ Stock Exchange
350
12-31
Common stock
12390 El Camino Real, San Diego, California, 92130
--
Halozyme Therapeutics, Inc., is a biopharmaceutical company founded in 1998. In November 2007, the company was reorganized and registered in Delaware (previously registered in Nevada). The company is committed to the development and commercialization of innovative products. The company studies extracellular matrix, extracellular regions, including cell migration, signaling and survival. Over the years, the company has developed unique scientific expertise that allows it to pursue treatments that focus on environmental development.
Earnings Call
Company Financials
EPS
HALO has released its 2025 Q1 earnings. EPS was reported at 1.11, versus the expected 0.94, beating expectations. The chart below visualizes how HALO has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
HALO has released its 2025 Q1 earnings report, with revenue of 264.86M, reflecting a YoY change of 35.22%, and net profit of 118.09M, showing a YoY change of 53.72%. The Sankey diagram below clearly presents HALO's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available